Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Verdict
Mostly mechanism / observational
Top outcomes
Liquid EPs 7630: 30 drops three times daily for adults during an acute infection
spread-through-day
Liquid extract (EPs 7630)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Days 4-7 of an acute episode
Within the acute illness window
During use
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Pelargonium sidoides extract for treating acute respiratory tract infections.
Cochrane Database Syst Rev (2013) · Systematic review · n=10 trials; ~746 adults and ~819 children
Liquid EPs 7630 showed effectiveness for acute bronchitis in both adults and children; tablets did not
Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.
Pediatr Int (2012) · Rct · n=220 children/adolescents
Significantly greater BSS reduction with EPs 7630 versus placebo (P<0.0001)
Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides.
Wien Med Wochenschr (2010) · Rct · n=406 adults
All three active dose groups improved patient-reported outcomes versus placebo at day 7
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 6.5/10) and wins in 2 of 3 categories.
No known interactions between Pelargonium Sidoides and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.